Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation
Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: alprazolam sublingual tablet commercial (Drug); alprazolam sublingual tablet test (Drug)
Phase: Phase 1
Sponsored by: Pfizer
Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
This study tests the assumption that the bioavailability of alprazolam from a new sublingual
formulation is the same as that from sublingual formulation expected to be used commercially
Official title: Open-label, Randomized, Single-dose, 2-way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Sublingual Tablet
Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Primary outcome: Alprazolam bioavailability assessed as area under the concentration-time curve (AUC) and maximum concentration (Cmax)
Alprazolam time of maximum concentration (Tmax) and half life
Adverse events, clinical laboratory tests, vital signs
Minimum age: 18 Years.
Maximum age: 55 Years.
- Healthy male or female subjects
- BMI 17. 5 - 30. 5
- Must provide informed consent
- Clinically significant disease
- Narrow angle glaucoma
- Positive drug screen
Locations and Contacts
To obtain contact information for a study center near you, click here.
Starting date: September 2012
Last updated: March 11, 2015